Catheter Precision (VTAK) Stock Surges 60% on Fly Flyte Aviation Deal

TLDR

• Catheter Precision ($VTAK) surged ~60% on Tuesday after announcing a merger agreement with Fly Flyte
• VTAK is acquiring the remaining 80.02% equity interest in Fly Flyte it doesn’t already own from Creatd ($CRTD)
• The deal is part of a broader set of agreements totalling $11.55 million, covering Flyte and Ponderosa
• The acquisition also included Ponderosa, which Catheter Precision is buying 100% of from Creatd
• To fund operations, the company launched a private placement of convertible preferred stock, raising an initial $1.85 million with an option to raise up to $35.56 million

Catheter Precision (VTAK) had a wild Tuesday.  The stock jumped nearly 60% after the company announced it is acquiring the remaining 80.02% equity interest in Fly Flyte, making it the full owner of the aviation business.

Catheter Precision, Inc., VTAK

The deal comes as part of a broader set of agreements. VTAK is also acquiring 100% of Ponderosa from Creatd. The combined purchase price for both Flyte and Ponderosa is $11.55 million, to be paid through a mix of cash, a 0% note, and Series D preferred stock.

Prior to this deal, VTAK already held a minority stake in Fly Flyte. Now, the company says all operations, assets, and financials from Fly Flyte will be fully folded into VTAK’s books.

Jenkins added that management believes full ownership of Flyte “materially enhances VTAK’s long-term valuation profile” by bringing in consolidated revenues and asset backing.

What VTAK Is Getting Out of the Deal

The company outlined several stated benefits from the acquisition. These include completing what it called a “transformative business combination,” expanding into asset-backed transportation infrastructure, and aligning capital, governance, and growth under a single structure.

VTAK also said the deal positions it for fleet expansion over time and creates what it described as operating leverage potential going forward.

The moves are also meant to restructure legacy businesses, simplify the balance sheet, and expand the company’s operating platform.

How the Deal Is Being Funded

To fund the acquisition and other strategic initiatives, Catheter Precision launched a multi-tranche private placement of convertible preferred stock. The company closed an initial tranche of $1.85 million and has set conditions for additional tranches, with an option to raise up to $35.56 million in total.

Dawson James Securities was retained as placement agent, with fees accruing above a $3.85 million threshold. VTAK also granted resale registration rights to both investors and Creatd as part of the arrangement.

On the trading side, the reaction was hard to miss. More than 25.7 million VTAK shares changed hands on Tuesday. That compares to the company’s three-month average daily volume of around 309,000 — roughly 83 times normal.

Before today’s move, VTAK was down 25.14% year-to-date and had fallen 81.1% over the past 12 months. The stock also dropped 2.84% the day before the announcement.

In pre-market trading on Tuesday, VTAK was already up 59.85% before markets opened, suggesting the news hit quickly after Monday evening’s announcement.

The deal for Flyte and Ponderosa was announced on March 9, 2026.

The post Catheter Precision (VTAK) Stock Surges 60% on Fly Flyte Aviation Deal appeared first on CoinCentral.